Viome
The company will use the funds to launch its diagnostics division and expand its offerings under the helm of its new chief operating officer.
The life sciences company's Gut Intelligence Test will be available in 200 CVS locations and through the drugstore chain online.
The clinical trial results will be used to expand Viome’s mRNA platform, which in May received FDA breakthrough device designation for identifying early signs of oral and throat cancers.
The partnership expands on the companies’ earlier collaboration announced in late 2019.
Viome has adapted its technology to search for the presence of oral squamous cell carcinoma and oropharyngeal cancer in users’ saliva samples.